Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 22585218)

1.

Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit.

Störzinger D, Borghorst S, Hofer S, Busch CJ, Lichtenstern C, Hempel G, Weigand MA, Hoppe-Tichy T.

Antimicrob Agents Chemother. 2012 Aug;56(8):4468-70. doi: 10.1128/AAC.06167-11. Epub 2012 May 14.

2.

Posaconazole plasma concentrations in critically ill patients.

Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D.

Ther Drug Monit. 2011 Aug;33(4):387-92. doi: 10.1097/FTD.0b013e31821fb197.

PMID:
21654350
3.

Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers.

Dodds Ashley ES, Varkey JB, Krishna G, Vickery D, Ma L, Yu X, Malavade D, Goodwin M, Perfect JR, Power E.

Antimicrob Agents Chemother. 2009 Jul;53(7):2960-4. doi: 10.1128/AAC.01178-08. Epub 2009 May 11.

4.

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.

Mohammedi I, Piens MA, Padoin C, Robert D.

Eur J Clin Microbiol Infect Dis. 2005 May;24(5):358-60. No abstract available.

PMID:
15875225
5.

Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.

Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P.

Clin Pharmacokinet. 2011 Nov 1;50(11):725-34. doi: 10.2165/11592630-000000000-00000.

PMID:
21973269
6.

Relevance of timing for determination of posaconazole plasma concentrations.

Heinz WJ, Zirkel J, Kuhn A, Schirmer D, Lenker U, Keller D, Klinker H.

Antimicrob Agents Chemother. 2011 Jul;55(7):3621-3. doi: 10.1128/AAC.00062-11. Epub 2011 Apr 18.

7.

HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.

Müller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M.

Mycoses. 2006;49 Suppl 1:17-22.

PMID:
16961577
8.

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, Cornely OA, Fuhr U, Kreuzer KA, Hallek M, Kohl V.

Eur J Clin Pharmacol. 2012 Jun;68(6):987-95. doi: 10.1007/s00228-012-1212-y.

PMID:
22286158
9.

Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation.

Kohl V, Müller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Rüping MJ.

Antimicrob Agents Chemother. 2010 Jan;54(1):207-12. doi: 10.1128/AAC.01027-09. Epub 2009 Oct 26.

10.

Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.

Cornely OA, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC.

Antimicrob Agents Chemother. 2012 May;56(5):2652-8. doi: 10.1128/AAC.05937-11. Epub 2012 Jan 30.

11.

Optimising absorption of posaconazole.

Green MR, Woolery JE.

Mycoses. 2011 Nov;54(6):e775-9. doi: 10.1111/j.1439-0507.2011.02020.x. Epub 2011 May 25.

PMID:
21615538
12.

Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.

Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, Saltzman MA.

Antimicrob Agents Chemother. 2006 May;50(5):1881-3.

13.

Posaconazole serum level on day 2 predicts steady state posaconazole serum level.

Green MR, Woolery JE.

Ther Drug Monit. 2012 Feb;34(1):118-9. doi: 10.1097/FTD.0b013e31823cef77. No abstract available.

PMID:
22249348
14.

Enteral fluconazole population pharmacokinetics in patients in the surgical intensive care unit.

Rajagopalan P, Pelz RK, Lipsett PA, Swoboda SM, Rinaldi MG, Hendrix CW.

Pharmacotherapy. 2003 May;23(5):592-602.

PMID:
12741433
15.

Intracellular concentrations of posaconazole in different compartments of peripheral blood.

Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Rüping MJ, Müller C.

Antimicrob Agents Chemother. 2010 Jul;54(7):2928-31. doi: 10.1128/AAC.01407-09. Epub 2010 May 10.

16.

A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.

Bryant AM, Slain D, Cumpston A, Craig M.

Int J Antimicrob Agents. 2011 Mar;37(3):266-9. doi: 10.1016/j.ijantimicag.2010.11.021. Epub 2011 Jan 13.

PMID:
21236645
17.

Posaconazole therapeutic drug monitoring: a reference laboratory experience.

Thompson GR 3rd, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS 2nd.

Antimicrob Agents Chemother. 2009 May;53(5):2223-4. doi: 10.1128/AAC.00240-09. Epub 2009 Mar 2. No abstract available.

19.

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.

Krishna G, Moton A, Ma L, Medlock MM, McLeod J.

Antimicrob Agents Chemother. 2009 Mar;53(3):958-66. doi: 10.1128/AAC.01034-08. Epub 2008 Dec 15.

20.

Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.

Matthias KR, Nix DE, Peloquin CA, Graham ML.

Ann Pharmacother. 2012 Sep;46(9):e22. doi: 10.1345/aph.1Q456. Epub 2012 Aug 7.

PMID:
22872751
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk